212 related articles for article (PubMed ID: 36860703)
1. Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.
Kwon M; Rubio G; Wang H; Riedlinger G; Adem A; Zhong H; Slegowski D; Post-Zwicker L; Chidananda A; Schrump DS; Pine SR; Libutti SK
Cancer Res Commun; 2022 Oct; 2(10):1197-1213. PubMed ID: 36860703
[TBL] [Abstract][Full Text] [Related]
2. FILIP1L Loss Is a Driver of Aggressive Mucinous Colorectal Adenocarcinoma and Mediates Cytokinesis Defects through PFDN1.
Kwon M; Rubio G; Nolan N; Auteri P; Volmar JA; Adem A; Javidian P; Zhou Z; Verzi MP; Pine SR; Libutti SK
Cancer Res; 2021 Nov; 81(21):5523-5539. PubMed ID: 34417201
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected].
Kwon M; Lee SJ; Reddy S; Rybak Y; Adem A; Libutti SK
PLoS One; 2013; 8(12):e82620. PubMed ID: 24340050
[TBL] [Abstract][Full Text] [Related]
4. Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis.
Kwon M; Lee SJ; Wang Y; Rybak Y; Luna A; Reddy S; Adem A; Beaty BT; Condeelis JS; Libutti SK
Int J Cancer; 2014 Jul; 135(1):48-60. PubMed ID: 24327474
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.
Burton ER; Gaffar A; Lee SJ; Adeshuko F; Whitney KD; Chung JY; Hewitt SM; Huang GS; Goldberg GL; Libutti SK; Kwon M
Mol Cancer Res; 2011 Aug; 9(8):1126-38. PubMed ID: 21693594
[TBL] [Abstract][Full Text] [Related]
7. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
8. Filamin A interacting protein 1-like as a therapeutic target in cancer.
Kwon M; Libutti SK
Expert Opin Ther Targets; 2014 Dec; 18(12):1435-47. PubMed ID: 25200207
[TBL] [Abstract][Full Text] [Related]
9. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
10. Filamin A interacting protein 1-like expression inhibits progression in colorectal cancer.
Park YL; Park SY; Lee SH; Kim RB; Kim JK; Rew SY; Myung DS; Cho SB; Lee WS; Kim HS; Joo YE
Oncotarget; 2016 Nov; 7(44):72229-72241. PubMed ID: 27750216
[TBL] [Abstract][Full Text] [Related]
11. STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/β-catenin signaling pathway.
Yang J; Liu Y; Mai X; Lu S; Jin L; Tai X
Biochem Biophys Res Commun; 2019 Jun; 514(1):118-126. PubMed ID: 31027730
[TBL] [Abstract][Full Text] [Related]
12. BARX1 repressed FOXF1 expression and activated Wnt/β-catenin signaling pathway to drive lung adenocarcinoma.
Guan X; Liang J; Xiang Y; Li T; Zhong X
Int J Biol Macromol; 2024 Mar; 261(Pt 2):129717. PubMed ID: 38290639
[TBL] [Abstract][Full Text] [Related]
13. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling.
Jiang N; Zou C; Zhu Y; Luo Y; Chen L; Lei Y; Tang K; Sun Y; Zhang W; Li S; He Q; Zhou J; Chen Y; Luo J; Jiang W; Ke Z
Theranostics; 2020; 10(6):2553-2570. PubMed ID: 32194819
[No Abstract] [Full Text] [Related]
14. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
15. CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/β-catenin signaling pathway.
Yao Y; Hua Q; Zhou Y
Biochem Biophys Res Commun; 2019 Jan; 508(1):37-45. PubMed ID: 30470570
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9.
Liang L; Xu WY; Shen A; Cen HY; Chen ZJ; Tan L; Zhang LM; Zhang Y; Fu JJ; Qin AP; Lei XP; Li SP; Qin YY; Huang JH; Yu XY
Acta Pharmacol Sin; 2022 Nov; 43(11):2946-2955. PubMed ID: 35388129
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma.
Cao Y; Geng J; Wang X; Meng Q; Xu S; Lang Y; Zhou Y; Qi L; Wang Z; Wei Z; Yu Y; Jin S; Pan B
Int J Biol Sci; 2022; 18(1):124-139. PubMed ID: 34975322
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.
Kwon M; Hanna E; Lorang D; He M; Quick JS; Adem A; Stevenson C; Chung JY; Hewitt SM; Zudaire E; Esposito D; Cuttitta F; Libutti SK
Cancer Res; 2008 Sep; 68(18):7332-41. PubMed ID: 18794120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
